A Potential Drug Target and Biomarker for Histone Demethylase H3-dimethyl-L-lysine (H3K12)

Target Name: HR

NCBI ID: G55806

Content of Review Report on HR Target / Biomarker

A Potential Drug Target and Biomarker for Histone Demethylase H3-dimethyl-L-lysine (H3K12)

Histone H3-dimethyl-L-lysine (H3K12) demethylase hairless (Dmh) is a gene that has been identified as a potential drug target in the field of human genetics. The H3K12 demethylase is a key enzyme that plays a role in the regulation of gene expression and is responsible for the removal of a methyl group from the Lys27 residue of histones, which is a common modification found in gene promoters. The hairless gene is associated with a range of genetic disorders, including Down syndrome, fragile X syndrome, and Charcot-Marie-Tooth disease.

In addition to its association with genetic disorders, Dmh has also been shown to play a role in the regulation of cellular processes such as cell growth, differentiation, and the immune response. The hairless gene has been shown to be involved in the development and maintenance of stem cells, and has also been shown to play a role in the regulation of the blood-brain barrier.

Dmh has also been shown to be involved in the regulation of fertility and reproductive processes. In male mice, Dmh has been shown to play a role in the regulation of sexual dimorphism and has been shown to contribute to the development of male reproductive organs. In female mice, Dmh has been shown to play a role in the regulation of ovarian development and has been shown to contribute to the development of early pregnancy.

In addition to its association with genetics and reproductive processes, Dmh has also been shown to play a role in the regulation of cellular signaling pathways. The hairless gene has been shown to be involved in the regulation of several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

Given its involvement in a range of cellular processes, Dmh has potential as a drug target. Studies have shown that inhibiting the activity of Dmh has the potential to treat a range of genetic disorders, including Down syndrome, fragile X syndrome, and Charcot-Marie-Tooth disease. In addition, inhibiting the activity of Dmh has been shown to have potential as a treatment for cancer, as it has been shown to have anti-tumor effects in both cancer cell lines and animals.

In addition to its potential as a drug target, Dmh has also been shown to be a potential biomarker. Studies have shown that the level of Dmh is significantly decreased in the brains of individuals with Down syndrome, and that inhibiting the activity of Dmh has the potential to improve cognitive function in these individuals. Similarly, studies have shown that the level of Dmh is significantly decreased in the hearts of individuals with fragile X syndrome, and that inhibiting the activity of Dmh has the potential to improve cardiac function in these individuals.

Overall, Dmh is a gene that has the potential to be a drug target and a biomarker. Further research is needed to fully understand its role in the regulation of gene expression and its potential as a drug and biomarker.

Protein Name: HR Lysine Demethylase And Nuclear Receptor Corepressor

Functions: Histone demethylase that specifically demethylates both mono- and dimethylated 'Lys-9' of histone H3. May act as a transcription regulator controlling hair biology (via targeting of collagens), neural activity, and cell cycle

The "HR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets